Gabapentin Capsule
Product Images NDC 63187-988

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63187-988). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Image 1)

1 (Image 1)
This text appears to be a formula for estimating the renal clearance (cLcr) of a patient based on their age and weight (in kg) along with their serum creatinine level (in mg/dL). Specifically, the formula states that cLcr is equal to 140 minus the patient's age in years multiplied by their weight in kg, and then adjusted for female patients by dividing the result by 85. This value is then divided by their serum creatinine level in mg/dL, which is multiplied by 72. The purpose of this formula is to help healthcare providers assess a patient's kidney function, as renal clearance is a key measure of how well the kidneys are able to filter waste products from the blood.*
FDA Label Image

1 (Image 11)

1 (Image 11)
FDA Label Image

63187-988-00 (Image 14)

63187-988-00 (Image 14)
This is a prescription drug identified as Gabapentin 300mg enclosed in 100 capsules per bottle. It is manufactured by Actavis Elizabeth LLC in Elizabeth, NJ, USA. The capsules are yellow and light brown with the logo "2666" printed on both the cap and body of the capsule in black ink. The drug should be stored at a temperature of 20°C-25°C (68°77°F) and kept out of children's reach. Each capsule contains Gabapentin, USP 300 mg. It is necessary to provide patients with a separate medication guide. Lot #00000 Exp 0000000. NOC 63187-98800 P!.*
FDA Label Image

1 (Image 2)

1 (Image 2)
FDA Label Image

1 (Image 3)

1 (Image 3)
FDA Label Image

1 (Image 4)

1 (Image 4)
FDA Label Image

1 (Image 5)

1 (Image 5)
FDA Label Image

1 (Image 6)

1 (Image 6)
The text provides a summary of the mean pain score observed during a clinical study that had a dose titration period of 4 weeks followed by a fixed dose period of 4 weeks. The study tested the effects of Gabapentin at a daily dose of 3600mg compared to a Placebo. However, no further information or context is available, making it difficult to draw any conclusions or provide a more detailed description.*
FDA Label Image

2 (Image 7)

2 (Image 7)
This is a report on the mean pain score with different doses of Gabapentin during different periods of treatment. The dosage of Gabapentin was either 1800 mg/day or 2400 mg/day. The periods during which the doses were administered were a 4-week fixed dose period and a titration period. The report also mentions the lack of a placebo group. However, there is not enough information provided to give any further context or interpretation.*
FDA Label Image

3 (Image 8)

3 (Image 8)
FDA Label Image

4 (Image 9)

4 (Image 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.